Research Site

Düsseldorf, North Rhine-Westphalia 40225

1 studies enrolling now · 13 studies all time

What they study most

Anemia, Chronic Obstructive Pulmonary Disease, Dialysis-Dependent Chronic Kidney Disease, Hypophosphatasia (HPP), Multiple Sclerosis, Non-Dialysis-Dependent Chronic Kidney Disease, Non-Small-Cell Lung Carcinoma, Progressive Multifocal Leukoencephalopathy, Relapsing Forms of Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Supranuclear Palsy, Progressive

Studies at this site

• Registry of Patients With Hypophosphatasia — Enrolling by invitation
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Plegridy Observational Program — Completed
• Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD) — Completed
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD) — Completed
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• Study of BIIB092 in Participants With Progressive Supranuclear Palsy — Stopped early
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis — Stopped early
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) — Completed
• Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) — Stopped early
• Iressa Versus Docetaxel (Taxotere) — Completed
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD — Completed